Q4 2025. Management View. CEO Joshua Riggs announced the submission of GraftAssureDx to the FDA, emphasizing, “ ...
Submitted GraftAssureDx for kidney transplant rejection testing for FDA review on Wednesday, March 25Welcomed second ...
Every at-home STI test uses a vaginal swab. Testmate Health's urine-based test works for everyone. Lab-quality results in ...
Submitted GraftAssureDx™ for kidney transplant rejection testing for FDA review on Wednesday, March 25Welcomed second ...
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q4 2025 Earnings Call Transcript March 26, 2026 Lucid Diagnostics Inc. misses on earnings expectations. Reported EPS is $-0.1 EPS, expectations were $-0.07.
Medical laboratory professionals in Nigeria have voiced strong opposition to proposed health reform legislation currently before the ...
Milestone marks first of multiple planned diagnostic product launches on NGS roadmap Powered by the Archer platform technology, IDT empowers molecular pathology laboratories with first in ...
While the effort could bring new requirements to the reimbursement process, it could also make payments more standardized and ...
The Wilms tumor protein market has shown substantial growth and is projected to continue expanding over the coming years. The ...
Novel marine mammal health surveillance can now detect deadly diseases in whales and dolphins in oceans, beaches and remote ...
O’Ryan Health is turning every home into a safe, reliable point of care. This partnership with Aura Genetics will accelerate access for families where travel to a lab can be a major obstacle.” — Tim ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results